Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
ROCKVILLE, Md., Feb. 27, 2018 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
[email protected]
Media
Adam Pawluk, 202-591-4063
[email protected]
